Heart failure - outlooks and strategies for treatment
Anne Keogh,
Corresponding Author
Anne Keogh
Senior Staff Cardiologist, St Vincent's Hospital, Sydney, NSW
St Vincent's Hospital, Darlinghurst 2010, NSWSearch for more papers by this authorAnne Keogh,
Corresponding Author
Anne Keogh
Senior Staff Cardiologist, St Vincent's Hospital, Sydney, NSW
St Vincent's Hospital, Darlinghurst 2010, NSWSearch for more papers by this authorFirst published: 25 March 2008
Abstract
The outlook in heart failure patients with a dilated cardiomyopathy has improved dramatically over the past ten years. The availability of many excellent drugs apart from angiotensin II converting enzyme inhibitors (ACEI) has contributed to this. The best current survival rates reported are, however, in association with deliberate optimisation of haemodynamic parameters and incorporation of functional testing to monitor disease progression. These practises could well be adopted more widely in Australia and New Zealand. Surgical options for heart failure continue to expand, but apart from heart transplantation, remain somewhat experimental.
References
- 1 The SOLVD Investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 292–302.
- 2 Fowler M. Selecting patients for cardiac transplantation; stratifying according to risk factor analysis (Abstr.). 3rd International Congress on Heart Failure. Geneva: 1995, May 21–25.
- 3 Lindelow B., Andersson B., Waagstein F., Bergh C-H. Prognosis of alternative therapies in patients with heart failure not accepted for heart transplantation. J Heart Lung Transplant 1995; 14: 1204–11.
- 4 Keogh A., Kaan A. The Australasian Cardiothoracic Organ Transplant Registry: First report 1984–1992. AustNZJ Med 1992; 22: 712–7.
- 5 Consensus I. Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429–35.
- 6 Hamer A., Arkles B., Johns J. Beneficial effects of low dose amiodarone in patients with congestive cardiac failure; a placebo controlled trial. J Am Coll Cardiol 1989; 14: 1768–74.
- 7 Bristow M., Lowes B. Low-dose inotropic therapy for ambulatory heart failure. Coronary Artery Dis 1994; 5: 2: 112–8.
- 8 Doval H., Nul D., Grancelli H., Perene S., Bortman G., Curiel R. Randomised trial of low dose amiodarone in severe congestive heart failure. Lancet 1994; 344: 493–8.
- 9 Dusman R., Stanton M., Miles W. et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation 1990; 82: 51–9.
- 10 Singh S., Fletcher R., Fisher S. et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333: 77–82.
- 11 Waagstein F., Bristow M., Swedberg K. et al. Beneficial effect of metoprolol in idiopathic dilated cardiomyopathy. Mctoprolol in Dilated Cardiomyopathy Trial Study Group. Lancet 1993; 342: 1441–6.
- 12 Australian and New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator B blocker, in patients with congestive heart failure due to ischaemic heart disease. Circulation 1995; 92: 2: 212–8.
- 13 Olsen S., Gilbert E., Renlund D., Taylor D., Yanowitz F., Bristow M. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double blind randomised study. J Am Coll Cardiol 1995; 25: 1225–31.
- 14 Packer M., Bristow M., Conn J., Colucci W., Fowler M., Gilbert E. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349–55.
- 15 Kalman J., Buchholz C., Steinmetz M. et al. Safety and efficacy of beta blockade in patients with chronic congestive heart failure awaiting transplantation. J Heart Lung Transplant 1995; 14: 1212–7.
- 16 Packer M., Gheorghiade M., Young J. et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. N Engl J Med 1993; 329: 1–7.
- 17 The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525–33.
- 18 Feldman A., Bristow M., Parmley W. et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med 1993; 329: 149–55.
- 19 Kubo S., Gollub S., Bourge R. et al. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure: results of a multicentre trial. Circulation 1992; 85: 3: 942–9.
- 20 Cohn J., Johnson G., Ziesche S. et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive cardiac failure. N Engl J Med 1991; 325: 303–10.
- 21 Fonarow G., Chemlimsky-Fallick C., Stevenson L. et al. Effect of direct vasodilatation with hydralazine versus angiotensin converting enzyme inhibition with captopril on mortality in advanced heart failure: The Hy-C trial. J Am Coll Cardiol 1992; 19: 842–50.
- 22 Consensus II., Swedberg K., Held P., Kjekshus J., Rasmussen K., Ryden L., Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction - results of the Cooperative New Scandinavian Enalapril Survival Study II (Consensus II). N Engl J Med 1992; 327: 678–84.
- 23 Mancini D., Eisen H., Kussmaul W. et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991; 83: 778–86.
- 24 Keogh A., Baron D., Hickie J. Prognostic guides in patients with idiopathic or ischaemic dilated cardiomyopathy assessed for cardiac transplantation. Am J Cardiol 1990; 65: 903–8.
- 25 Stevenson L., Perliff J. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989; 261: 6: 884–8.
- 26 Stevenson L., Tillisch J., Hamilton M. Importance of hemodynamic response to therapy in predicting survival with ejection fraction <20% secondary to ischemic or non-ischemic dilated cardiomyopathy. Am J Cardiol 1990; 66: 1348–54.
- 27 Levine T., Goldberg D., Narins B., Goldstein S., Lesch M. Reversal of end-stage heart failure is predicted by long-term therapeutic response rather than initial hemodynamic and neurohumoral profile. J Heart Lung Transplant 1996; 15: 297–303.
- 28 Imai T., Saitoh K., Kani H., Fujita T., Murata K. Combined dose ratios of dopamine and dobutamine and right ventricular performance after cardiac surgery. Chest 1992; 101: 1197–202.
- 29 Leier C. Current status of non-digitalis positive inotropic drugs. Am J Cardiol 1992; 69: 120G–129G.
- 30 Unverferth D., Magorien R., Altschuld R., Kolibash A., Lewis R., Leier C. The hemodynamic and metabolic advantages gained by a 3 day infusion of dobutamine in patients with congestive cardiomyopathy. Am Heart J 1983; 106: 29–34.
- 31 Krell M., Kline E., Bates E. et al. Intermittent ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J 1986; 112: 787–91.
- 32 Sindone A., Keogh A., Macdonald P., McCosker C. Cost effectiveness of home ambulatory inotrope therapy in severe heart failure. J Heart Lung Transplant 1995; 14: S85.
- 33 Hall D., Zeitler H., Werner R. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992; 20: 1549–55.
- 34 Pitt B. Use of converting enzyme inhibitors in patients with asymptomatic left ventricular dysfunction. J Am Coll Cardiol 1993; 22 (Suppl. A): 158–161A.
- 35 Cleland J. ACE inhibitors for myocardial infarction; how should they be used Eur Heart J 1995; 16: 153–9.
- 36
Nguyen K.,
Aursnes I.,
Snappin S.,
Kjekshur J.
Antagonism between enalapril and aspirin; subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II).
J Am Coll Cardiol
1995; 25 (Suppl. A): 23A.
10.1016/0735-1097(95)91553-A Google Scholar
- 37 Middlekauf H., Stevenson W., Stevenson L. Prognostic significance of atrial fibrillation in advanced heart failure; a study of 390 patients. Circulation 1991; 84: 1: 40–8.
- 38 McKelvie R., Koon K., McCartney N., Humen D., Montague T., Yusuf S. Effects of exercise training in patients with congestive cardiac failure: a critical review. J Am Coll Cardiol 1995; 25: 789–96.
- 39 Louie H., Laks H., Milgalter E. et al. Ischaemic cardiomyopathy - criteria for coronary revascularisation and cardiac transplantation. Circulation 1995; 84 (Suppl. Ill): III290–III295.
- 40 Jatene A., Moreira L., Stolf N. et al. Left ventricular functional changes after cardiomyoplasty in patients with dilated cardiomyopathy. J Thoracic Cardiovasc Sgy 1991; 102: 132–9.
- 41 Chachques J., Grandjean P., Pfeffer T. et al. Cardiac assistance by atrial or ventricular cardiomyoplasty. J Heart Transplant 1990; 9: 239–51.
- 42 Barbier P., Gerometta P., Tamborini G., Biglioli P., Sisillo E., Guazzi M. Acute effects of dynamic cardiomyoplasty on ventricular geometry and left ventricular filling detected by transoesophageal doppler echocardiography. Am J Cardiol 1996; 77: 9: 783–7.
- 43 Bocchi E., Guimaraes G., Moreira L. et al. Peak oxygen consumption and resting left ventricular ejection fraction changes after cardiomyoplasty at 6 months followup. Circulation 1995; 92 (Suppl. II): II107.
- 44 Moraes A., Bellotti G., Bocchi E. et al. Pattern of left ventricular dynamics and diastolic filling one year after successful cardiomyoplasty. J Heart Lung Transplant 1994; 13: S37.
